Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 9/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069264 | 1.00 | MAOB (0.49) | MAOBMAOAKCNH2CYP2C19BDKRB1 | |
| SCHEMBL9968660 | 0.93 | MAOB (0.48) | MAOBMAOAKCNH2CYP2C19BDKRB1 | |
| SCHEMBL9930537 | 0.89 | KCNH2 (0.51) | MAOBMAOAKCNH2CYP2C19PDE10A | |
| SCHEMBL9930911 | 0.89 | MAOB (0.57) | MAOBMAOAKCNH2BDKRB1FFAR1 | |
| SCHEMBL9930239 | 0.88 | MAOB (0.45) | MAOBMAOAKCNH2CYP2C19PDE10A | |
| SCHEMBL9930165 | 0.86 | MAOB (0.49) | MAOBMAOAKCNH2BDKRB1FFAR1 | |
| SCHEMBL9930162 | 0.84 | MAOA (0.49) | MAOBMAOACYP2C9 | |
| SCHEMBL14069262 | 0.84 | MAOA (0.49) | MAOBMAOACYP2C9 | |
| SCHEMBL13429544 | 0.83 | MAOB (0.46) | MAOBMAOAKCNH2BDKRB1PDE10A | |
| SCHEMBL13429548 | 0.83 | MAOB (0.46) | MAOBMAOAKCNH2BDKRB1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | MAOB 761/4885MAOA 1058/4885KCNH2 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.